natgillin/translations-raw huggingface dataset:
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter EU/1/09/583/025-048
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets EU/1/09/583/025-048
Derfor frarådes brug af Irbesartan/Hydrochlorthiazid Teva.
Therefore, the use of Irbesartan/Hydrochlorothiazide Teva is not recommended.
Halveringstiden for hydrochlorthiazid forlænges til 21 timer hos patienter med kreatininclearance < 20 ml/min.
In patients with creatinine clearance < 20 ml/min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
Dosisjustering af Irbesartan/Hydrochlorthiazid Teva til patienter med mild eller moderat leverfunktionsnedsættelse er ikke nødvendig (se pkt.
No dosage adjustment of Irbesartan/Hydrochlorothiazide Teva is necessary in patients with mild to moderate hepatic impairment (see section 4.3).
Non-melanom hudkræft: Tilgængelige data fra epidemiologiske studier viser en kumulativ dosisafhængig forbindelse mellem hydrochlorthiazid og non-melanom hudkræft.
Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed.
Artralgi, myalgi
Swelling extremity Arthralgia, myalgia
Luftveje, thorax og mediastinum
Respiratory, thoracic and mediastinal disorders:
Anvendelse af Irbesartan/Hydrochlorothiazide Teva i ammeperioden frarådes.
The use of Irbesartan/Hydrochlorothiazide Teva during breast feeding is not recommended.
Virkningen af pressoraminer kan nedsættes, men ikke tilstrækkeligt til at udelukke deres anvendelse;
Pressor amines (e.g. noradrenaline) The effect of pressor amines may be decreased, but not sufficiently to preclude their use;
Forholdet mellem den laveste og den maksimale effekt var henholdsvis 68 % og 76 % for irbesartan/hydrochlorthiazid 150 mg /12,5 mg og irbesartan/hydrochlorthiazid 300 mg /12,5 mg, når effekten blev målt med blodtryksmanchet ved kontrolbesøg.
The trough to peak effects measured by cuff during office visits were 68 % and 76 % for irbesartan/hydrochlorothiazide 150 mg/12.5 mg and irbesartan/hydrochlorothiazide 300 mg/12.5 mg, respectively.
Elektrolytforstyrrelser
Electrolyte imbalance
• Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg kan gives til patienter, der er utilstrækkeligt regulerede med Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg.
• Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg may be administered in patients insufficiently controlled by Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg.
Ortostatisk svimmelhed
Vascular disorders:
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter EU/1/09/583/001-024
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets EU/1/09/583/001-024
• Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg kan gives til patienter, der er utilstrækkeligt regulerede med irbesartan 300 mg eller med Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg.
• Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg.
Yderligere information om irbesartaninteraktioner Irbesartans farmakokinetik er i kliniske forsøg ikke blevet påvirket af hydrochlorthiazid.
In clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Den anden side af tabletten er præget med tallet "7239".
The other side of the tablet debossed with the number "7239".
Pakningsstørrelser og yderligere oplysninger Irbesartan/hydrochlorthiazid Teva indeholder:
Contents of the pack and other information What Irbesartan/Hydrochlorothiazide Teva contains
Lægen vil sandsynligvis starte behandling med Irbesartan/Hydrochlorthiazid Teva, hvis den tidligere behandling for forhøjet blodtryk ikke har haft tilstrækkelig effekt.
Irbesartan/Hydrochlorothiazide Teva will usually be prescribed by your doctor when your previous treatment for high blood pressure did not provide appropriate blood pressure reduction.
Nervesystemet
Nervous system disorders:
Kombination af irbesartan/hydrochlorthiazid
Irbesartan/hydrochlorothiazide combination
Hver filmovertrukket tablet indeholder 300 mg irbesartan og 25 mg hydrochlorthiazid
Each film-coated tablet contains 300 mg irbesartan and 25 mg hydrochlorothiazide
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg
Patienter, der planlægger at blive gravide, bør skifte til anden antihypertensiv behandling hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA'er skønnes nødvendig.
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Patienter, der planlægger at blive gravide, bør skifte til anden antihypertensiv behandling, hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA skønnes nødvendig.
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Særlige patientgrupper
Special Populations
FREMSTILLER(E) ANSVARLIG(E) FOR BATCHFRIGIVELSE
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Tabletovertræk for styrken 150 mg/12,5 mg: Hypromellose, titandioxid, polyethylenglycol 6000 (macrogol), polyethylenglycol 400 (macrogol), rød jernoxid, gul jernoxid og sort jernoxid.
Tablet coating for 150 mg/12.5 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, iron oxide yellow and iron oxide black.
Tillæg af 12,5 mg hydrochlorthiazid til 300 mg irbesartan 1 gang dagligt hos patienter, der ikke er tilstrækkeligt behandlede med 300 mg irbesartan alene, medførte yderligere placebo-korrigeret diastolisk blodtryksreduktion ved laveste måling (24 timer efter dosis) på 6,1 mm Hg. Kombinationen af 300 mg irbesartan og 12,5 mg hydrochlorthiazid medførte en total placebo-korrigeret systolisk/diastolisk reduktion på op til 13,6/11,5 mm Hg.
The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mmHg.
Lithium Kombination af lithium og Irbesartan/Hydrochlorthiazid Teva frarådes (se pkt.
Lithium The combination of lithium and Irbesartan/Hydrochlorothiazide Teva is not recommended (see section 4.5).
Tabletovertræk for styrken 300 mg/25 mg: Hypromellose, titandioxid, polyethylenglycol 6000 (macrogol), polyethylenglycol 400 (macrogol), rød jernoxid, Indigotin (Indigocarmin) og sort jernoxid.
Tablet coating for 300 mg/25 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, Indigotine (Indigo carmine aluminium lake FD&C blue #2) and iron oxide black.
Et randomiseret, dobbeltblindt, aktivt kontrolleret, parallelt multicenterforsøg af 8 ugers varighed har evalueret effekten og sikkerheden af irbesartan/hydrochlorthiazid som initial behandling ved svær hypertension (defineret som SeDBT ≥ 110 mm Hg).
Efficacy and safety of irbesartan/hydrochlorothiazide as initial therapy for severe hypertension (defined as SeDBP ≥ 110 mmHg) was evaluated in a multicentre, randomised, double-blind, active-controlled, 8-week, parallel-arm study.
Samtidig administration af irbesartan ændrer det kalium-tab, der er forbundet med disse diuretika, formodentligt ved at blokere renin-angiotensin-aldosteronsystemet.
Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics.
Derfor frarådes kombination af lithium og Irbesartan/Hydrochlorthiazid Teva (se pkt.
Therefore, the combination of lithium and Irbesartan/Hydrochlorothiazide Teva is not recommended (see section 4.4).
Non-melanom hudkræft: Tilgængelige data fra epidemiologiske studier viser en kumulativ dosisafhængig forbindelse mellem hydrochlorthiazid og non-melanom hudkræft (se også pkt.
Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).
Brug af anden medicin sammen med Irbesartan/Hydrochlorthiazid Teva
Other medicines and Irbesartan/Hydrochlorothiazide Teva
Tabletovertræk for styrken 300 mg/12,5 mg: Hypromellose, titandioxid, polyethylenglycol 6000 (macrogol), polyethylenglycol 400 (macrogol), rød jernoxid, gul jernoxid og sort jernoxid.
Tablet coating for 300 mg/12.5 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, iron oxide yellow and iron oxide black.
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg
Der er dog rapporteret minimal eller ingen effekt ved en dosis på 12,5 mg, som findes i kombinationen af irbesartan og hydrochlorthiazid.
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in the irbesartan and hydrochlorothiazide combination, minimal or no effects were reported.
Hver filmovertrukket tablet indeholder 150 mg irbesartan og 12,5 mg hydrochlorthiazid
Each film-coated tablet contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide
Irbesartans farmakokinetiske parametre ændres ikke væsentligt hos patienter med mild/moderat cirrhose.
In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter irbesartan/hydrochlorthiazid
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide
Hver filmovertrukket tablet indeholder 300 mg irbesartan og 12,5 mg hydrochlorthiazid
Each film-coated tablet contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide
LISTE OVER HJÆLPESTOFFER LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE)
PHARMACEUTICAL FORM AND CONTENTS
Hvis du drikker alkohol, mens du er i behandling med dette produkt, kan du opleve, at du bliver mere svimmel, især når du rejser dig op fra siddende stilling.
Due to the hydrochlorothiazide contained in Irbesartan/Hydrochlorothiazide Teva, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.
Administration Til oral brug.
For oral use.
≥ 100 mg/kg/dag hos makakaber) en reduktion i røde blodlegemeparametre (erytrocytter, hæmoglobin, hæmatokrit).
caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit).
Hydrochlorthiazids fotosensibiliserende virkning kan være en mulig mekanisme i forhold til non-melanom hudkræft.
Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC.
Sådan skal du tage Irbesartan/Hydrochlorthiazid Teva
How to take Irbesartan/Hydrochlorothiazide Teva
Indlægsseddel: Information til brugeren Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter irbesartan / hydrochlorthiazid
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 300 mg irbesartan og 25 mg hydrochlorthiazid.
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets Each film-coated tablet contains 300 mg of irbesartan and 25 mg of hydrochlorothiazide.
Hvis du får et eller flere af disse symptomer eller får åndenød, skal du holde op med at tage
If you get any of these symptoms or get short of breath, stop taking Irbesartan/Hydrochlorothiazide Teva and contact your doctor immediately.
Begrænsede kliniske data (7 patienter ud af 22) tyder på, at patienter, som ikke er regulerede med 300 mg/12,5 mg-kombinationen, kan respondere ved dosisøgning til 300/25 mg. Der er hos disse patienter observeret en øgning i blodtryksreduktionen for såvel systolisk blodtryk (SBP) som diastolisk blodtryk (DBP) (henholdsvis 13,3 mm Hg og 8,3 mm Hg).
Limited clinical data (7 out of 22 patients) suggest that patients not controlled with the 300 mg/12.5 mg combination may respond when uptitrated to 300 mg/25 mg.
Thiaziddiuretika øger urinudskillelse og sænker derved blodtrykket.
Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes increased urine output and so causes a lowering of blood pressure.
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 150 mg irbesartan og 12,5 mg hydrochlorthiazid.
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Each film-coated tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Indlægsseddel: Information til brugeren Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter irbesartan / hydrochlorthiazid
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter irbesartan/hydrochlorthiazid
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter irbesartan/hydrochlorthiazid
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Det skal du vide, før du begynder at tage Irbesartan/Hydrochlorthiazid Teva Sådan skal du tage Irbesartan/Hydrochlorthiazid Teva Bivirkninger
What Irbesartan/Hydrochlorothiazide Teva is and what it is used for What you need to know before you take Irbesartan/Hydrochlorothiazide Teva How to take Irbesartan/Hydrochlorothiazide Teva Possible side effects
Der er hverken observeret rebound-hypertension for irbesartan eller hydrochlorthiazid.
Although not specifically studied with irbesartan/hydrochlorothiazide, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.
Indlægsseddel: Information til brugeren Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter irbesartan / hydrochlorthiazid
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Forholdet mellem den laveste og den maksimale effekt af irbesartan/hydrochlorthiazid 150 mg/12,5 mg var 100 %, når blodtrykket blev monitoreret ambulant.
When measured by ambulatory blood pressure monitoring, the trough to peak effects of irbesartan/hydrochlorothiazide 150 mg/12.5 mg were 100 %.
Irbesartan/Hydrochlorthiazid Teva skal tages gennem munden.
Irbesartan/Hydrochlorothiazide Teva is for oral use.
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter Pink til mørk pink filmovertrukne kapselformede tabletter.
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets Pink to dark pink, film-coated capsule shaped tablet.
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 300 mg irbesartan og 12,5 mg hydrochlorthiazid.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Each film-coated tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Sort jernoxid
Iron Oxide Black
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter er pink til mørke pink, filmovertrukne kapselformede tabletter.
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets are pink to dark pink, film coated capsule shaped tablet.
Irbesartans farmakokinetiske parametre ændres ikke væsentligt hos patienter med nedsat nyrefunktion eller i hæmodialyse.
In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Dosisjustering er ikke nødvendig til patienter med nedsat nyrefunktion, hvis den renale kreatininclearance er > 30 ml/min (se pkt.
No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is ≥ 30 ml/min (see sections 4.3 and 4.4).
Benigne, maligne og uspecificerede tumorer (inkl.
Adverse reactions reported with the use of hydrochorothiazide alone Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypotension og takykardi forventes at være de mest sandsynlige symptomer på irbesartanoverdosering.
The most likely manifestations of irbesartan overdose are expected to be hypotension and tachycardia; bradycardia might also occur.
Øget serumcarbamid, kreatinin og kreatinkinase
Increases in blood urea nitrogen (BUN), creatinine and creatine kinase Decreases in serum potassium and sodium
Svækkelse, muskelspasmer bindevæv Vaskulære sygdomme
Musculoskeletal and connective tissue disorders:
Systemorganklasse
Method of Administration
Amning
Flushing
Om nødvendigt kan Irbesartan/Hydrochlorthiazid Teva kombineres med andre antihypertensiva (se pkt.
When necessary, Irbesartan/HydrochlorothiazideTeva may be administered with another antihypertensive medicinal product (see sections 4.3, 4.4, 4.5 and 5.1).
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter Lys pink til pink, filmovertrukne kapselformede tabletter.
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Light pink to pink, film-coated capsule shaped tablet.
6.1, eller over for andre sulfonamidderivater (hydrochlorthiazid er et sulfonamidderivat)
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance) Second and third trimester of pregnancy (see sections 4.4 and 4.6) Severe renal impairment (creatinine clearance < 30 ml/min) Refractory hypokalaemia, hypercalcaemia
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter Lys pink til pink, filmovertrukne kapselformede tabletter.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Light pink to pink, film-coated capsule shaped tablet.
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter er lyse pink til pink, filmovertrukne kapselformede tabletter.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter er lyse pink til pink, filmovertrukne kapselformede tabletter.
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Omvendt kan der opstå hyperkaliæmi på grund af irbesartankomponenten i Irbesartan/Hydrochlorthiazid Teva.
Conversely, due to the irbesartan component of Irbesartan/Hydrochlorothiazide Teva hyperkalaemia might occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus.
Oversigt over indlægssedlen:
Psychiatric disorders:
Gul jernoxid
Digitalis glycosides
Irbesartan forebygger at angiotensin-II binder sig til disse receptorer.
Irbesartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
• Aktive stoffer: Irbesartan og hydrochlorthiazid Hver Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukket tablet indeholder 300 mg irbesartan og 25 mg hydrochlorthiazid.
Each Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablet contains 300 mg irbesartan and 25 mg hydrochlorothiazide.
• Samtidig brug af Irbesartan/Hydrochlorthiazid Teva og lægemidler indeholdende aliskiren er kontraindiceret hos patienter med diabetes mellitus eller nedsat nyrefunktion (GFR
Severe hepatic impairment, biliary cirrhosis and cholestasis The concomitant use of Irbesartan/Hydrochlorothiazide Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
• hvis du oplever øget følsomhed af huden for sol med solskoldningssymptomer (såsom rødme, kløe, hævelse, blæredannelse), som forekommer hurtigere end normalt
if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal if you are going to have an operation (surgery) or be given anaesthetics if you have changes in your vision or pain in one or both of your eyes while taking Irbesartan/Hydrochlorothiazide Teva.
• Aktive stoffer: Irbesartan og hydrochlorthiazid Hver Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukket tablet indeholder 300 mg irbesartan og 12,5 mg hydrochlorthiazid.
Each Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablet contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
• Aktive stoffer: Irbesartan og hydrochlorthiazid Hver Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukket tablet indeholder 150 mg irbesartan og 12,5 mg hydrochlorthiazid.
Each Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablet contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Hvis du har taget for mange Irbesartan/Hydrochlorthiazid Teva tabletter
If you take more Irbesartan/Hydrochlorothiazide Teva than you should
Betingelser for markedsføringstilladelse
Marketing Authorisation Holder
- Find en bekvem og stabil position.
- Put yourself in a comfortable and stable position.
- Hvis du har diabetes.
- if you have diabetes.
Efter første åbning: 4 uger.
After first opening: 4 weeks.
Behandlingseffekten blev evalueret i op til 29 dage.
Treatment effect was evaluated up to 29 days.
Brug hos voksne, inklusive ældre patienter
Use in adults, including the elderly
In vitro var 99,8 % bundet til proteiner i humant plasma.
In vitro, the 99.8% were bound to proteins in human plasma.
Pakken indeholder 1 flaske.
Pack of 1 bottle.
Der er ikke udført interaktionsundersøgelser.
No interaction studies have been performed.
Dato for første markedsføringstilladelse:18.05.2011 Dato for seneste fornyelse:11.01.2016
Date of first authorisation: 18.05.2011 Date of latest renewal: 11.01.2016
- Vask hænderne inden du bruger øjendråberne.
- Wash your hands before using the eye drops.
Skyl øjet med varmt vand.
Rinse out your eye with warm water.
Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.
By reporting side effects you can help provide more information on the safety of this medicine.
Brug ikke Yellox længere end 2 uger.
Do not use Yellox longer than 2weeks.
Brug en enkelt dosis, så snart du kommer i tanke om det.
Use a single dose as soon as you remember.
- Hvis du har fået gentagne øjenoperationer inden for et kort tidsrum.
- if you had repeated eye surgery within a short period of time.
- Hvis du har rheumatoid arthritis (leddegigt).
- if you have rheumatoid arthritis.
*Alvorlige rapporter fra erfaring efter markedsføring med flere end 20 millioner patienter ** Observeret ved dosering fire gange daglig
*Serious reports from post-marketing experience of more than 20 million patients ** Observed with four times daily dose
Behandlingen bør ikke overstige 2 uger, da der ikke foreligger sikkerhedsdata for behandling ud over dette tidsrum.
The treatment should not exceed 2 weeks as safety data beyond this is not available.
Disse hændelser kan true synet.
These events may be sight threatening.